The US consumer price index rose 0.6% in September from a month earlier, and 3.7% on an annual basis, according to the Bureau of Labor Statistics. The data shows gas prices rose by 9.1%. Bloomberg's Michael McKee has the initial reading.
The Progressive Corporation (NYSE:PGR) reported third-quarter 2026 financial results, with earnings per share of $4.37 compared with analyst expectations of $4.42.
Sarepta Therapeutics (NASDAQ:SRPT) presented new preclinical findings from its SRP-1003 program at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS).
Iran-backed Houthis launched missile and drone attacks across Saudi Arabia, hitting oil giant Saudi Aramco's headquarters, as well several cities in the kingdom. Abeer Abu Omar reports on Bloomberg Television.
Viking Therapeutics (NASDAQ:VKTX) announced the start of its SUNRISE Phase 3 clinical program for oral VK2735, an investigational therapy being developed for obesity management.
Alpha Compute (NASDAQ:ALP) announced that it entered into a binding GPU compute services agreement on October 9, 2026, for its first contracted U.S. GPU cluster.
Parabilis Medicines (NASDAQ:PBLS) announced the initiation of a new dose-ranging cohort for zolucatetide in adults with familial adenomatous polyposis, a hereditary condition associated with the development of precancerous polyps.
Guillaume Princen, Anthropic Head of International Startups & Digital Native, joins Bloomberg's Tom Mackenzie on "The Opening Trade" to discuss how artificial intelligence will impact businesses, customer spending on frontier models, and AI safety risks. They speak from the International AI Summit in Dublin, Ireland.
Christopher Hodge, chief US economist at Natixis, expects core CPI to come in slightly softer than forecast and sees inflation continuing to ease. He discusses the impact of higher energy prices, potential labor market weakness and housing pressures, while forecasting one final Fed rate hike in December before the tightening cycle ends. He spoke on Bloomberg Brief.
Takeda Pharmaceutical (NYSE:TAK) presented new data from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating TAK-881 Immune Globulin Subcutaneous (Human), 20% Solution combined with recombinant human hyaluronidase.
Morgan Stanley saw third quarter profit rise as the firm's equity traders topped analysts' estimates and a record amount of money was brought in by the bank's wealth-management operation. Kristine Aquino reports on Bloomberg Television.
Entrada Therapeutics (NASDAQ:TRDA) announced that an independent monitoring committee has recommended initiating Cohort 3 of its Phase 1/2 ELEVATE-44-201 clinical study.
